| __timestamp | Ligand Pharmaceuticals Incorporated | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 72471000 |
| Thursday, January 1, 2015 | 24378000 | 89204000 |
| Friday, January 1, 2016 | 26621000 | 106010000 |
| Sunday, January 1, 2017 | 28653000 | 137905000 |
| Monday, January 1, 2018 | 37734000 | 159888000 |
| Tuesday, January 1, 2019 | 41884000 | 158425000 |
| Wednesday, January 1, 2020 | 64435000 | 200677000 |
| Friday, January 1, 2021 | 57483000 | 304759000 |
| Saturday, January 1, 2022 | 70062000 | 377221000 |
| Sunday, January 1, 2023 | 52790000 | 336361000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus consistently outpaced Ligand, with its SG&A expenses growing by over 360%, peaking in 2022. In contrast, Ligand's expenses increased by approximately 130% during the same period, with a notable spike in 2022. This divergence highlights Supernus's aggressive expansion strategy compared to Ligand's more conservative approach. The data suggests that while both companies are investing in growth, Supernus is prioritizing rapid scaling, potentially positioning itself for greater market share. As the pharmaceutical industry evolves, these spending patterns offer insights into each company's strategic priorities and market positioning.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Supernus Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.